Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 28 entries
Sorted by: Best Match Show Resources per page
Epidemiology and clinical outcome of patients hospitalized with pelvic inflammatory disease complicated by tubo-ovarian abscess.

Infectious diseases in obstetrics and gynecology

Chan Y, Parchment W, Skurnick JH, Goldsmith L, Apuzzio JJ.
PMID: 18476036
Infect Dis Obstet Gynecol. 1995;3(4):135-9. doi: 10.1155/S1064744995000470.

OBJECTIVE: The purpose of this retrospective study was to compare the clinical outcome and characteristics of pelvic inflammatory disease (PID) complicated by tubo-ovarian abscess (TOA) with PID without TOA.METHODS: Chart reviews were performed for all PID admissions to the...

Cite
Chan Y, Parchment W, Skurnick JH, et al. Epidemiology and clinical outcome of patients hospitalized with pelvic inflammatory disease complicated by tubo-ovarian abscess. Infect Dis Obstet Gynecol. 1995;3(4):135-9doi: 10.1155/S1064744995000470.
Chan, Y., Parchment, W., Skurnick, J. H., Goldsmith, L., & Apuzzio, J. J. (1995). Epidemiology and clinical outcome of patients hospitalized with pelvic inflammatory disease complicated by tubo-ovarian abscess. Infectious diseases in obstetrics and gynecology, 3(4), 135-9. https://doi.org/10.1155/S1064744995000470
Chan, Y, et al. "Epidemiology and clinical outcome of patients hospitalized with pelvic inflammatory disease complicated by tubo-ovarian abscess." Infectious diseases in obstetrics and gynecology vol. 3,4 (1995): 135-9. doi: https://doi.org/10.1155/S1064744995000470
Chan Y, Parchment W, Skurnick JH, Goldsmith L, Apuzzio JJ. Epidemiology and clinical outcome of patients hospitalized with pelvic inflammatory disease complicated by tubo-ovarian abscess. Infect Dis Obstet Gynecol. 1995;3(4):135-9. doi: 10.1155/S1064744995000470. PMID: 18476036; PMCID: PMC2364435.
Copy Download .nbib Format: NLM
The Incidence of Workplace Bullying and Related Environmental Factors Among Nurse Managers.

The Journal of nursing administration

Parchment J, Andrews D.
PMID: 30789556
J Nurs Adm. 2019 Mar;49(3):132-137. doi: 10.1097/NNA.0000000000000726.

OBJECTIVE: The purpose of the study was to explore relationships between authentic leadership style, global social power, job demand, job control, and workplace bullying of nurse managers in acute care settings across the United States.BACKGROUND: Consequences of workplace bullying...

Cite
Parchment J, Andrews D. The Incidence of Workplace Bullying and Related Environmental Factors Among Nurse Managers. J Nurs Adm. 2019;49(3):132-137doi: 10.1097/NNA.0000000000000726.
Parchment, J., & Andrews, D. (2019). The Incidence of Workplace Bullying and Related Environmental Factors Among Nurse Managers. The Journal of nursing administration, 49(3), 132-137. https://doi.org/10.1097/NNA.0000000000000726
Parchment, Joy, and Andrews, Diane. "The Incidence of Workplace Bullying and Related Environmental Factors Among Nurse Managers." The Journal of nursing administration vol. 49,3 (2019): 132-137. doi: https://doi.org/10.1097/NNA.0000000000000726
Parchment J, Andrews D. The Incidence of Workplace Bullying and Related Environmental Factors Among Nurse Managers. J Nurs Adm. 2019 Mar;49(3):132-137. doi: 10.1097/NNA.0000000000000726. PMID: 30789556.
Copy Download .nbib Format: NLM
Social support and school outcomes of adolescents orphaned and made vulnerable by HIV/AIDS living in South Western Uganda.

Vulnerable children and youth studies

Osuji HL, Nabunya P, Byansi W, Parchment TM, Ssewamala F, McKay MM, Huang KY.
PMID: 30083221
Vulnerable Child Youth Stud. 2018;13(3):228-238. doi: 10.1080/17450128.2018.1439211. Epub 2018 Feb 23.

The goal of this study is to examine the role of social support from multiple sources, including the extended family, caregivers, classmates, peers and teachers, in improving the school outcomes (grades and attendance) of children orphaned by AIDS in...

Cite
Osuji HL, Nabunya P, Byansi W, et al. Social support and school outcomes of adolescents orphaned and made vulnerable by HIV/AIDS living in South Western Uganda. Vulnerable Child Youth Stud. 2018;13(3):228-238doi: 10.1080/17450128.2018.1439211.
Osuji, H. L., Nabunya, P., Byansi, W., Parchment, T. M., Ssewamala, F., McKay, M. M., & Huang, K. Y. (2018). Social support and school outcomes of adolescents orphaned and made vulnerable by HIV/AIDS living in South Western Uganda. Vulnerable children and youth studies, 13(3), 228-238. https://doi.org/10.1080/17450128.2018.1439211
Osuji, Hadiza L, et al. "Social support and school outcomes of adolescents orphaned and made vulnerable by HIV/AIDS living in South Western Uganda." Vulnerable children and youth studies vol. 13,3 (2018): 228-238. doi: https://doi.org/10.1080/17450128.2018.1439211
Osuji HL, Nabunya P, Byansi W, Parchment TM, Ssewamala F, McKay MM, Huang KY. Social support and school outcomes of adolescents orphaned and made vulnerable by HIV/AIDS living in South Western Uganda. Vulnerable Child Youth Stud. 2018;13(3):228-238. doi: 10.1080/17450128.2018.1439211. Epub 2018 Feb 23. PMID: 30083221; PMCID: PMC6075833.
Copy Download .nbib Format: NLM
The association between self-Esteem, stigma, and mental health among South African youth living with HIV: the need for integrated HIV care services.

AIDS care

Small LA, Huynh AK, Parchment TM.
PMID: 34839770
AIDS Care. 2021 Nov 27;1-9. doi: 10.1080/09540121.2021.2002253. Epub 2021 Nov 27.

Treatment among pYLHIV focuses on their physical health. However, they also experience depression and anxiety, compounded by developmental challenges and the stress of managing a chronic illness. However, limited services are available to help pYLHIV manage the emotional stressors...

Cite
Small LA, Huynh AK, Parchment TM. The association between self-Esteem, stigma, and mental health among South African youth living with HIV: the need for integrated HIV care services. AIDS Care. 2021;1-9doi: 10.1080/09540121.2021.2002253.
Small, L. A., Huynh, A. K., & Parchment, T. M. (2021). The association between self-Esteem, stigma, and mental health among South African youth living with HIV: the need for integrated HIV care services. AIDS care, 1-9. https://doi.org/10.1080/09540121.2021.2002253
Small, Latoya A, et al. "The association between self-Esteem, stigma, and mental health among South African youth living with HIV: the need for integrated HIV care services." AIDS care vol. (2021): 1-9. doi: https://doi.org/10.1080/09540121.2021.2002253
Small LA, Huynh AK, Parchment TM. The association between self-Esteem, stigma, and mental health among South African youth living with HIV: the need for integrated HIV care services. AIDS Care. 2021 Nov 27;1-9. doi: 10.1080/09540121.2021.2002253. Epub 2021 Nov 27. PMID: 34839770.
Copy Download .nbib Format: NLM
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research

Takebe N, Naqash AR, O'Sullivan Coyne G, Kummar S, Do K, Bruns A, Juwara L, Zlott J, Rubinstein L, Piekarz R, Sharon E, Streicher H, Mittra A, Miller SB, Ji J, Wilsker D, Kinders RJ, Parchment RE, Chen L, Chang TC, Das B, Mugundu G, Doroshow JH, Chen AP.
PMID: 33863809
Clin Cancer Res. 2021 Jul 15;27(14):3834-3844. doi: 10.1158/1078-0432.CCR-21-0329. Epub 2021 Apr 16.

PURPOSE: The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase II dose (RPh2D). Here, we report results for once-daily adavosertib.PATIENTS AND...

Cite
Takebe N, Naqash AR, O'Sullivan Coyne G, et al. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021;27(14):3834-3844doi: 10.1158/1078-0432.CCR-21-0329.
Takebe, N., Naqash, A. R., O'Sullivan Coyne, G., Kummar, S., Do, K., Bruns, A., Juwara, L., Zlott, J., Rubinstein, L., Piekarz, R., Sharon, E., Streicher, H., Mittra, A., Miller, S. B., Ji, J., Wilsker, D., Kinders, R. J., Parchment, R. E., Chen, L., Chang, T. C., Das, B., Mugundu, G., Doroshow, J. H., & Chen, A. P. (2021). Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(14), 3834-3844. https://doi.org/10.1158/1078-0432.CCR-21-0329
Takebe, Naoko, et al. "Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,14 (2021): 3834-3844. doi: https://doi.org/10.1158/1078-0432.CCR-21-0329
Takebe N, Naqash AR, O'Sullivan Coyne G, Kummar S, Do K, Bruns A, Juwara L, Zlott J, Rubinstein L, Piekarz R, Sharon E, Streicher H, Mittra A, Miller SB, Ji J, Wilsker D, Kinders RJ, Parchment RE, Chen L, Chang TC, Das B, Mugundu G, Doroshow JH, Chen AP. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 Jul 15;27(14):3834-3844. doi: 10.1158/1078-0432.CCR-21-0329. Epub 2021 Apr 16. PMID: 33863809; PMCID: PMC8282703.
Copy Download .nbib Format: NLM
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas.

Oncotarget

Coyne GO, Kummar S, Meehan RS, Do K, Collins JM, Anderson L, Ishii K, Takebe N, Zlott J, Juwara L, Piekarz R, Streicher H, Sharon E, Rubinstein L, Voth AR, Lozier J, Dull AB, Wilsker D, Hinoue T, Laird PW, Ferry-Galow KV, Kinders RJ, Parchment RE, Doroshow JH, Chen AP.
PMID: 33216844
Oncotarget. 2020 Nov 03;11(44):3959-3971. doi: 10.18632/oncotarget.27784. eCollection 2020 Nov 03.

BACKGROUND: TRC102 inhibits base excision repair by binding abasic sites and preventing AP endonuclease processing; it potentiates the activity of alkylating agents, including temozolomide, in murine models. In published xenograft studies, TRC102 enhanced the antitumor effect of temozolomide regardless...

Cite
Coyne GO, Kummar S, Meehan RS, et al. Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. Oncotarget. 2020;11(44):3959-3971doi: 10.18632/oncotarget.27784.
Coyne, G. O., Kummar, S., Meehan, R. S., Do, K., Collins, J. M., Anderson, L., Ishii, K., Takebe, N., Zlott, J., Juwara, L., Piekarz, R., Streicher, H., Sharon, E., Rubinstein, L., Voth, A. R., Lozier, J., Dull, A. B., Wilsker, D., Hinoue, T., Laird, P. W., Ferry-Galow, K. V., Kinders, R. J., Parchment, R. E., Doroshow, J. H., & Chen, A. P. (2020). Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. Oncotarget, 11(44), 3959-3971. https://doi.org/10.18632/oncotarget.27784
Coyne, Geraldine O'Sullivan, et al. "Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas." Oncotarget vol. 11,44 (2020): 3959-3971. doi: https://doi.org/10.18632/oncotarget.27784
Coyne GO, Kummar S, Meehan RS, Do K, Collins JM, Anderson L, Ishii K, Takebe N, Zlott J, Juwara L, Piekarz R, Streicher H, Sharon E, Rubinstein L, Voth AR, Lozier J, Dull AB, Wilsker D, Hinoue T, Laird PW, Ferry-Galow KV, Kinders RJ, Parchment RE, Doroshow JH, Chen AP. Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. Oncotarget. 2020 Nov 03;11(44):3959-3971. doi: 10.18632/oncotarget.27784. eCollection 2020 Nov 03. PMID: 33216844; PMCID: PMC7646836.
Copy Download .nbib Format: NLM
Building the Science to Guide Nursing Administration and Leadership Decision Making.

The Journal of nursing administration

Joseph ML, Nelson-Brantley HV, Caramanica L, Lyman B, Frank B, Hand MW, Parchment J, Ward DM, Weatherford B, Chipps E.
PMID: 34897205
J Nurs Adm. 2021 Dec 09; doi: 10.1097/NNA.0000000000001098. Epub 2021 Dec 09.

OBJECTIVE: The aim of this study was to identify the challenges, barriers, and solutions for conducting nursing administration and leadership science (NALS) research.BACKGROUND: Evidence from leadership science should be at the forefront of nurse leaders' decision making. Yet, challenges...

Cite
Joseph ML, Nelson-Brantley HV, Caramanica L, et al. Building the Science to Guide Nursing Administration and Leadership Decision Making. J Nurs Adm. 2021;doi: 10.1097/NNA.0000000000001098.
Joseph, M. L., Nelson-Brantley, H. V., Caramanica, L., Lyman, B., Frank, B., Hand, M. W., Parchment, J., Ward, D. M., Weatherford, B., & Chipps, E. (2021). Building the Science to Guide Nursing Administration and Leadership Decision Making. The Journal of nursing administration, . https://doi.org/10.1097/NNA.0000000000001098
Joseph, M Lindell, et al. "Building the Science to Guide Nursing Administration and Leadership Decision Making." The Journal of nursing administration vol. (2021). doi: https://doi.org/10.1097/NNA.0000000000001098
Joseph ML, Nelson-Brantley HV, Caramanica L, Lyman B, Frank B, Hand MW, Parchment J, Ward DM, Weatherford B, Chipps E. Building the Science to Guide Nursing Administration and Leadership Decision Making. J Nurs Adm. 2021 Dec 09; doi: 10.1097/NNA.0000000000001098. Epub 2021 Dec 09. PMID: 34897205.
Copy Download .nbib Format: NLM
Filling the Knowledge Gap for Nurse Leaders: Next Steps Following COVID-19.

Nurse leader

Hand MW, Alexander C, Lyman B, Parchment J, Joseph ML, Chipps E.
PMID: 34335118
Nurse Lead. 2021 Dec;19(6):616-621. doi: 10.1016/j.mnl.2021.07.005. Epub 2021 Jul 28.

The purpose of this article is to share gaps in knowledge and research related to pandemic management identified by nurse leaders during the COVID-19 pandemic. As part of a larger Delphi study, nurse leaders responded to an open-ended question...

Cite
Hand MW, Alexander C, Lyman B, et al. Filling the Knowledge Gap for Nurse Leaders: Next Steps Following COVID-19. Nurse Lead. 2021;19(6):616-621doi: 10.1016/j.mnl.2021.07.005.
Hand, M. W., Alexander, C., Lyman, B., Parchment, J., Joseph, M. L., & Chipps, E. (2021). Filling the Knowledge Gap for Nurse Leaders: Next Steps Following COVID-19. Nurse leader, 19(6), 616-621. https://doi.org/10.1016/j.mnl.2021.07.005
Hand, Mikel W, et al. "Filling the Knowledge Gap for Nurse Leaders: Next Steps Following COVID-19." Nurse leader vol. 19,6 (2021): 616-621. doi: https://doi.org/10.1016/j.mnl.2021.07.005
Hand MW, Alexander C, Lyman B, Parchment J, Joseph ML, Chipps E. Filling the Knowledge Gap for Nurse Leaders: Next Steps Following COVID-19. Nurse Lead. 2021 Dec;19(6):616-621. doi: 10.1016/j.mnl.2021.07.005. Epub 2021 Jul 28. PMID: 34335118; PMCID: PMC8316134.
Copy Download .nbib Format: NLM
Magnet® and Pathway to Excellence®: Focusing on Research and Evidence-Based Practice.

The Journal of nursing administration

Nelson-Brantley HV, Beckman D, Parchment J, Smith-Miller CA, Weaver SH.
PMID: 32317565
J Nurs Adm. 2020 May;50(5):245-247. doi: 10.1097/NNA.0000000000000877.

Healthcare organizations seeking to achieve or maintain Magnet or Pathway to Excellence designation are increasingly challenged to demonstrate how nurses are leading or are engaged in research and evidence-based practice. This article describes common barriers to and effective strategies...

Cite
Nelson-Brantley HV, Beckman D, Parchment J, et al. Magnet® and Pathway to Excellence®: Focusing on Research and Evidence-Based Practice. J Nurs Adm. 2020;50(5):245-247doi: 10.1097/NNA.0000000000000877.
Nelson-Brantley, H. V., Beckman, D., Parchment, J., Smith-Miller, C. A., & Weaver, S. H. (2020). Magnet® and Pathway to Excellence®: Focusing on Research and Evidence-Based Practice. The Journal of nursing administration, 50(5), 245-247. https://doi.org/10.1097/NNA.0000000000000877
Nelson-Brantley, Heather V, et al. "Magnet® and Pathway to Excellence®: Focusing on Research and Evidence-Based Practice." The Journal of nursing administration vol. 50,5 (2020): 245-247. doi: https://doi.org/10.1097/NNA.0000000000000877
Nelson-Brantley HV, Beckman D, Parchment J, Smith-Miller CA, Weaver SH. Magnet® and Pathway to Excellence®: Focusing on Research and Evidence-Based Practice. J Nurs Adm. 2020 May;50(5):245-247. doi: 10.1097/NNA.0000000000000877. PMID: 32317565.
Copy Download .nbib Format: NLM
Effective implementation of novel MET pharmacodynamic assays in translational studies.

Annals of translational medicine

Srivastava AK, Navas T, Herrick WG, Hollingshead MG, Bottaro DP, Doroshow JH, Parchment RE.
PMID: 28164088
Ann Transl Med. 2017 Jan;5(1):3. doi: 10.21037/atm.2016.12.78.

MET tyrosine kinase (TK) dysregulation is significantly implicated in many types of cancer. Despite over 20 years of drug development to target MET in cancers, a pure anti-MET therapeutic has not yet received market approval. The failure of two...

Cite
Srivastava AK, Navas T, Herrick WG, et al. Effective implementation of novel MET pharmacodynamic assays in translational studies. Ann Transl Med. 2017;5(1):3doi: 10.21037/atm.2016.12.78.
Srivastava, A. K., Navas, T., Herrick, W. G., Hollingshead, M. G., Bottaro, D. P., Doroshow, J. H., & Parchment, R. E. (2017). Effective implementation of novel MET pharmacodynamic assays in translational studies. Annals of translational medicine, 5(1), 3. https://doi.org/10.21037/atm.2016.12.78
Srivastava, Apurva K, et al. "Effective implementation of novel MET pharmacodynamic assays in translational studies." Annals of translational medicine vol. 5,1 (2017): 3. doi: https://doi.org/10.21037/atm.2016.12.78
Srivastava AK, Navas T, Herrick WG, Hollingshead MG, Bottaro DP, Doroshow JH, Parchment RE. Effective implementation of novel MET pharmacodynamic assays in translational studies. Ann Transl Med. 2017 Jan;5(1):3. doi: 10.21037/atm.2016.12.78. PMID: 28164088; PMCID: PMC5253289.
Copy Download .nbib Format: NLM
Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.

Oncotarget

Dull AB, Wilsker D, Hollingshead M, Mazcko C, Annunziata CM, LeBlanc AK, Doroshow JH, Kinders RJ, Parchment RE.
PMID: 29682208
Oncotarget. 2018 Mar 30;9(24):17104-17116. doi: 10.18632/oncotarget.24936. eCollection 2018 Mar 30.

DNA double strand breaks (DSBs) induced by cancer therapeutic agents can lead to DNA damage repair or persistent DNA damage, which can induce apoptotic cell death; however, apoptosis also induces DSBs independent of genotoxic insult. γH2AX is an established...

Cite
Dull AB, Wilsker D, Hollingshead M, et al. Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis. Oncotarget. 2018;9(24):17104-17116doi: 10.18632/oncotarget.24936.
Dull, A. B., Wilsker, D., Hollingshead, M., Mazcko, C., Annunziata, C. M., LeBlanc, A. K., Doroshow, J. H., Kinders, R. J., & Parchment, R. E. (2018). Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis. Oncotarget, 9(24), 17104-17116. https://doi.org/10.18632/oncotarget.24936
Dull, Angie B, et al. "Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis." Oncotarget vol. 9,24 (2018): 17104-17116. doi: https://doi.org/10.18632/oncotarget.24936
Dull AB, Wilsker D, Hollingshead M, Mazcko C, Annunziata CM, LeBlanc AK, Doroshow JH, Kinders RJ, Parchment RE. Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis. Oncotarget. 2018 Mar 30;9(24):17104-17116. doi: 10.18632/oncotarget.24936. eCollection 2018 Mar 30. PMID: 29682208; PMCID: PMC5908309.
Copy Download .nbib Format: NLM
Regenerative medicine therapy for single ventricle congenital heart disease.

Translational pediatrics

Ambastha C, Bittle GJ, Morales D, Parchment N, Saha P, Mishra R, Sharma S, Vasilenko A, Gunasekaran M, Al-Suqi MT, Li D, Yang P, Kaushal S.
PMID: 29770299
Transl Pediatr. 2018 Apr;7(2):176-187. doi: 10.21037/tp.2018.04.01.

One of the most complex forms of congenital heart disease (CHD) involving single ventricle physiology is hypoplastic left heart syndrome (HLHS), characterized by underdevelopment of the left ventricle (LV), mitral and aortic valves, and narrowing of the ascending aorta....

Cite
Ambastha C, Bittle GJ, Morales D, et al. Regenerative medicine therapy for single ventricle congenital heart disease. Transl Pediatr. 2018;7(2):176-187doi: 10.21037/tp.2018.04.01.
Ambastha, C., Bittle, G. J., Morales, D., Parchment, N., Saha, P., Mishra, R., Sharma, S., Vasilenko, A., Gunasekaran, M., Al-Suqi, M. T., Li, D., Yang, P., & Kaushal, S. (2018). Regenerative medicine therapy for single ventricle congenital heart disease. Translational pediatrics, 7(2), 176-187. https://doi.org/10.21037/tp.2018.04.01
Ambastha, Chetan, et al. "Regenerative medicine therapy for single ventricle congenital heart disease." Translational pediatrics vol. 7,2 (2018): 176-187. doi: https://doi.org/10.21037/tp.2018.04.01
Ambastha C, Bittle GJ, Morales D, Parchment N, Saha P, Mishra R, Sharma S, Vasilenko A, Gunasekaran M, Al-Suqi MT, Li D, Yang P, Kaushal S. Regenerative medicine therapy for single ventricle congenital heart disease. Transl Pediatr. 2018 Apr;7(2):176-187. doi: 10.21037/tp.2018.04.01. PMID: 29770299; PMCID: PMC5938254.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 28 entries